← Back to Clinical Trials
Recruiting NCT06892847

NCT06892847 Brain STimulation for ANxiety and Depression in Youth

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06892847
Status Recruiting
Phase
Sponsor University of Calgary
Condition Anxiety Disorders
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2025-07-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Transcranial Magnetic Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2025-07-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this open-label trial, the overall aim is to determine if TMS treatment can improve anxiety and depression in a broad group of children and youth referred by physicians.

Eligibility Criteria

Inclusion Criteria: 1. aged between 6 and 18 years old 2. diagnosis of anxiety or depression made by a qualified medical professional 3. active anxiety and/or depression symptoms Exclusion Criteria: 1. status epilepticus in past 12-months 2. presence of any disease, medical condition, or physical condition that, in the opinion of the study investigator may compromise, interfere, limit, affect, or reduce the participant's ability to complete the study 3. hospitalization for suicide attempt within the past 3 months (unless participant is under the daily supervision of a physician, such as in a mental health day treatment program) 4. TMS-related contraindications, including implanted medical devices (e.g., pacemaker) 5. if actively taking prescription medication, no changes in medication for at least 3 months prior to entry into the study, with no anticipation of change in the frequency or dose over the duration of the study, unless changes to medication are required for participant safety 6. unable to understand instructions in English

Contact & Investigator

Central Contact

Kara Murias, MD/PhD

✉ krmarten@ucalgary.ca

📞 1 403-441-8411

Principal Investigator

Kara Murias, MD/PhD

PRINCIPAL INVESTIGATOR

The University of Calgary

Frequently Asked Questions

Who can join the NCT06892847 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Anxiety Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06892847 currently recruiting?

Yes, NCT06892847 is actively recruiting participants. Contact the research team at krmarten@ucalgary.ca for enrollment information.

Where is the NCT06892847 trial being conducted?

This trial is being conducted at Calgary, Canada.

Who is sponsoring the NCT06892847 clinical trial?

NCT06892847 is sponsored by University of Calgary. The principal investigator is Kara Murias, MD/PhD at The University of Calgary. The trial plans to enroll 120 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology